Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer

Exclusion Criteria

• •Diagnosis of any malignant disease other than primary liver cancer within 3 years prior to enrollment
• •Currently participating in another interventional clinical study
• •History of allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
• •Presence of any severe or uncontrolled systemic disease
• •Any medical history, comorbid condition, treatment, or abnormal laboratory finding that may interfere with study results or hinder full participation, or any other situation that the investigator considers inappropriate for enrollment
• •Investigator's judgment of other potential risks making the patient unsuitable for participation in this study